Solid Biosciences and NanoMosaic Announce Co-Marketing Agreement to Advance Gene Therapy Delivery and Analytics

▤ Summary

Solid Biosciences and NanoMosaic have formed a co-marketing agreement to promote complementary gene therapy delivery and analytics technologies. The partnership pairs Solid’s POLARIS-101 capsid platform with NanoMosaic’s Tessie analytics system to help developers better characterize AAV products and improve regulatory readiness. The companies position the collaboration as a way to simplify workflows, reduce measurement bias, and increase confidence in product composition and dose understanding. The announcement also highlights NanoMosaic’s FDA AMT designation, which may help support adoption in gene therapy development and manufacturing.

▦ Linked Companies